Timothy Weeden
Chief Scientific Officer
Timothy Weeden brings over 25 years of experience in the discovery and development of oligonucleotides, small molecules, peptides and antibody therapeutics across areas of oncology, immunology and rare diseases.
Most recently, at Dyne Therapeutics, Mr. Weeden initiated research efforts focused on the design and development of the FORCE Platform, advancing two neuromuscular clinical programs and leading the broader implementation of the pipeline and second-generation products. Mr. Weeden has over 50 issued patents and has authored a number of peer-reviewed articles published in leading scientific journals.
Mr. Weeden obtained a BS in biochemistry from Bridgewater State University.